# Portal Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/portal-biotech-2

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.portalbiotech.com
- Total disclosed funding: $35M
- Latest round: Series A (Jun 20, 2025)
- Investors on record: 10

## About

Portal Biotech Limited, based in the UK, specializes in advanced proteomics technology, developing innovative instruments for comprehensive protein characterization and analysis for various research and industrial applications.Founded in 2021 and headquartered in London, UK, Portal Biotech Limited focuses on single-molecule proteomics. The company has engaged in one deal, raising USD 35.00 mn in Series A funding on June 30, 2025, from investors including NATO Innovation Fund and Earlybird Venture Capital, among others. This funding allows the company to enhance its infrastructure and applications in biosecurity.Portal Biotech specializes in single-molecule proteomics, offering innovative bench-top instruments for protein characterization. Utilizing nanopore technology, their platform provides high sensitivity analysis for a range of proteins and metabolites. Their machine learning algorithms interpret electrical signatures produced by molecules, enabling precise insights into protein identity and modifications. The instruments serve a diverse clientele, including academic institutions and biopharmaceutical companies across North America, Europe, and Asia.Portal Biotech generates revenue through protein characterization services and the sale of proprietary bench-top instruments, primarily targeting academic and commercial laboratories. Their B2B model allows clients to access real-time protein sample analyses and tailored workflows, with pricing based on service complexity and duration. Their flagship nanopore-based analysis platform plays a key role in supporting proteomic and metabolomic research needs.Following the USD 35.00 mn raised in Series A funding on June 30, 2026, Portal Biotech plans to enhance infrastructure and develop applications in biosecurity, supporting partnerships with pharmaceutical and biotech firms. The company aims to introduce new products and expand into emerging markets, although specific release dates and targeted regions have yet to be disclosed. The recent funding will significantly bolster their operational capabilities and support their growth strategy.

## Funding rounds

- Series A, Jun 20, 2025, $35M — Earlybird, WS Investments, 8VC, Pillar, NATO Innovation Fund, Science Creates Ventures, Amino Collective, Outsized Ventures, We Venture Capital, British Business Bank

## Investors

- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series A
- WS Investments (https://capitalatlas.ai/funds/ws-investments) — Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A
- Pillar (https://capitalatlas.ai/funds/pillar) — Series A
- NATO Innovation Fund (https://capitalatlas.ai/funds/nato-innovation-fund) — Series A
- Science Creates Ventures (https://capitalatlas.ai/funds/science-creates-ventures) — Series A
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Series A
- Outsized Ventures (https://capitalatlas.ai/funds/outsized-ventures) — Series A
- We Venture Capital (https://capitalatlas.ai/funds/we-venture-capital) — Series A
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series A